Individualized Prophylactic Treatment with Recombinant Factor VIII in Severe or Moderate Haemophilia a Patients. Association Between Pharmacokinetic Parameters and Clinical Variables

被引：0

作者：

Megias-Vericat, Juan Eduardo ^{[1
,2
]}

Marques, Maria Remedios ^{[1
]}

Haya, Saturnino ^{[3
]}

Cid, Ana Rosa ^{[3
]}

Querol, Felipe ^{[3
]}

Monte, Emilio ^{[1
,3
]}

Garcia-Dasi, Maria ^{[3
]}

Caunedo, Patricia ^{[3
]}

Vila, Carmen ^{[3
]}

Bosch, Pau ^{[3
]}

Curats, Rafael ^{[3
]}

Sanz, Miguel Angel ^{[4
]}

Poveda, Jose Luis ^{[1
,2
]}

Bonanad, Santiago ^{[5
]}

机构：

[1] Hosp Univ & Politecn La Fe, Dept Pharm, Drug Clin Area, Valencia, Spain

[2] Inst Invest Sanit La Fe, Valencia, Spain

[3] Hosp Univ & Politecn La Fe, Dept Hematol, Hemostasis & Thrombosis Unit, Valencia, Spain

[4] Hosp Univ & Politecn La Fe, Dept Hematol, Valencia, Spain

[5] Hosp La Ribera, Alzira, Spain

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.3802.3802

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3802

引用

页数：4

共 50 条

[1] Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A
Megias-Vericat, J. E.
Bonanad, S.
Haya, S.
Cid, A. R.
Marques, M. R.
Monte, E.
Perez-Alenda, S.
Bosch, P.
Querol, F.
Poveda, J. L.
THROMBOSIS RESEARCH, 2019, 174 : 151 - 162
[2] Physician preferences for medication attributes for the prophylactic treatment of patients with severe haemophilia A with inhibitors to factor VIII
Gelhorn, H.
Merikle, E.
Krishnan, S.
Nemes, L.
Leissinger, C.
Valentino, L.
HAEMOPHILIA, 2013, 19 (01) : 119 - 125
[3] Bayesian pharmacokinetic individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A
Eduardo Megias-Vericat, Juan
Marques, Remedios
Haya, Saturnino
Rosa Cid, Ana
Querol, Felipe
Monte, Emilio
Bosch, Pau
Curats, Rafael
Luis Poveda, Jose
Bonanad, Santiago
HAEMOPHILIA, 2018, 24 : 26 - 26
[4] Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A
Carlsson, M
Berntorp, E
Bjorkman, S
Lethagen, S
Ljung, R
HAEMOPHILIA, 1997, 3 (02) : 96 - 101
[5] Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres
Morfini, M.
Auerswald, G.
Kobelt, R. A.
Rivolta, G. F.
Rodriguez-Martorell, J.
Scaraggi, F. A.
Altisent, C.
Blatny, J.
Borel-Derlon, A.
Rossi, V.
HAEMOPHILIA, 2007, 13 (05) : 502 - 507
[6] Evaluation of liposomal dose in recombinant factor VIII reconstituted with pegylated liposomes for the treatment of patients with severe haemophilia A
Spira, Jack
Plyushch, Olga R.
Andreeva, Tatyana A.
Khametova, Rosa N.
THROMBOSIS AND HAEMOSTASIS, 2008, 100 (03) : 429 - 434
[7] Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B
Wang, C.
Young, G.
HAEMOPHILIA, 2018, 24 (03) : 414 - 419
[8] Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT® in patients with severe haemophilia A without inhibitors
Alvarez-Roman, M. T.
Fernandez-Bello, I.
de la Corte-Rodriguez, H.
Hernandez-Moreno, A. L.
Martin-Salces, M.
Butta-Coll, N.
Rivas-Pollmar, M. I.
Rivas-Munoz, S.
Jimenez-Yuste, V.
HAEMOPHILIA, 2017, 23 (01) : E50 - E54
[9] Population pharmacokinetic analysis of long-lasting recombinant factor VIII Fc fusion protein (rFVIIIFc) in patients with severe haemophilia A
Neelakantan, S.
Li, S.
Powell, J.
Josephson, N.
Pasi, J.
Perry, D.
Shapiro, A. D.
Ragni, M.
Kulkarni, R.
Fogarty, P.
Brennan, A.
Pierce, G.
Jiang, H.
Nestorov, I
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 354 - 355
[10] Recombinant Fusion Factor VIII-Fc Fusion Protein in Severe Haemophilia A Patients
Le Quellec, Sandra
HEMATOLOGIE, 2014, 20 (06): : 304 - 306

← 1 2 3 4 5 →